Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus;Tratamiento con rituximab para la trombocitopenia secundaria a lupus eritematoso sistémico

Reumatologia Clinica

Volumn 6, Issue 2, 2010, Pages 82-85

  Calderón Saldierna, Rosa Elena ^a   Ramos Sánchez, María Azucena ^a   Mejía Holguín, Yadhira ^a   Aranda Baca, Laura Elena ^a   Sauza del Pozo, María Josefina ^a   Becerra Márquez, Ariana Maia ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Anti CD20; Rituximab; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; HUMAN; INFECTION; RELAPSE; REMISSION; RESPONSE TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 75849154758     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.04.013     Document Type: Article

References (24)

1. Rahman A., and Isenberg D. Systemic Lupus Erythematosus, Mechanisms of disease. N Engl J Med 358 (2008) 929-939
2. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. European Working Party on Systemic lupus erythematosus.Morbidity and Mortality in Systemic Lupus Erythematosus during a 10-Year period. A comparision of Early and Late Manifestations in a Cohort of 1,000 patients. Medicine 82 (2003) 299-308
3. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
4. Moss K., Ioannou Y., Sultan S.M., Haq I., and Isenberg D.A. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61 (2002) 409-413
5. Ward M.M., Pyun E., and Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 156 (1996) 1337-1344
6. Roach B., and Hutchinson G. Treatment of refractory systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide. Arthritis Rheum 36 (1993) 682-684
7. Godeau B., Oksenhendler E., and Bierling P. Dapsone for autoimmune thrombocytopenic purpura. Am J Hematology 44 (1993) 70-72
8. Cervera H., Jara L.J., Pizarro S., Enkerlin H.L., Fernandez M., Medina F., et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' Syndrome. J Rheumatol 22 (1995) 1867-1871
9. Calverley D., Jones G., and Kelton J. Splenic radiation for corticosteroid-resistant immune thrombocytopenia. Ann Intern Med 116 12 Pt 1 (1992) 977-981
10. Silverman G., and Weisman S. Rituximab therapy and Autoimmune Disorders. Arthritis Rheum 48 (2003) 1484-1492
11. Gorman C., Leandro M., and Isenberg D. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?. Lupus 13 (2004) 312-316
12. Mantadakis E., Danilatou V., Stiakaki E., and Kalmati M. Rituximab for refractory Evans Syndrome and other immune-mediated hematologic diseases. Am J Hematol 77 (2004) 303-310
13. Ahrens N., Heymann G., Meyer O., Kiesewetter H., and Salama A. Results of treatment with rituximab in three patients with autoimmune hemolytic anemia and or immune thrombocytopenia and a concise review of reported cases. Infusionsther Transfusions Med 29 (2002) 277-281
14. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40 (2001) 205-211
15. Looney R.J., Anolik J., and Sanz I. Treatment of SLE with Anti-CD20 Monoclonal Antibody. Curr Dir Autoimmun 8 (2005) 193-205
16. Fra G.P., Avanzi G.C., and Bartoli E. Remission of refractory lupus nephritis whit a protocol including rituximab. Lupus 12 (2003) 783-787
17. Garcia-Chavez J., Majluf-Cruz A., Montiel-Cervantes L., Esparza M.G., Vela-Ojeda J., and Mexican Hematology Study Group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow up analysis. Ann Hematol 86 (2007) 871-877
18. Garcia-Hernandez F.J., Díaz-Cobos C., Callejas-Rubio J.L., Ocaña-Medina C., Ortego-Centeno N., Sánchez-Román J., et al. Experiencia con rituximab en el tratamiento de pacientes con lupus eritematoso sistémico. Reumatol Clin 2 (2006) 23-30
19. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
20. Braendstrup P., Bjerrum O.W., Nielsen O.J., Jensen B.A., Clausen N.T., Hansen P.B., et al. Rituximab chimeric anti-CD 20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78 (2005) 275-280
21. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M., Leonard J., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 (2004) 232-239
22. Leandro M.J., Cambridge G., Edwards J.C., Edwards J., Ehrenstein M.R., and Isenberg D.A. B cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44 (2005) 1542-1545
23. Gillis J.Z., Dall′era M., Gross A., Yazdany J., and Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57 (2007) 538-542
24. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B Cell depletion as a novel treatment for systemic lupus erytrematosus. Arthritis Rheum 50 (2004) 2580-2589